The supplementary protection certificate is a vital piece of patent protection to ensure pharmaceutical, biotech and medical device organisations can extend their product lifecycles. This session will provide invaluable information through two parts, the first a keynote address by the head of the German Patent and Trademark Office’s SPC Working Group, and the second, an interactive in-house panel discussion on how SPCs influence, not only IP, but business decisions as well.   PART I: Keynote Address on Recent SPC Decisions from the European Court of Justice This keynote session will address in detail the key takeaways and amendments following the most recent SPC decisions coming from the European Court of Justice.

• The results of the SPC consultation and recent decisions
• The scope of SPCs
• Analysis of whether something that has been disclosed in a patent application can be used as basis for an SPC?
• How to calculate SPCs: what is the duration from beginning to end?

  PART II: In-House Counsel Perspectives on the IP and Business Implications of SPCs

• Impact of recent case law
• What potential effect will these decisions have on my future business strategy?
• Implementing the most recent European Commission updates into practical IP and litigation strategies
• How will these decisions impact the future of SPC medical device applications?